Scott Moomaw Sells 18,314 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 18,314 shares of the stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $36.79, for a total value of $673,772.06. Following the transaction, the insider directly owned 187,640 shares in the company, valued at approximately $6,903,275.60. This represents a 8.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Scott Moomaw also recently made the following trade(s):

• On Monday, January 12th, Scott Moomaw sold 20,533 shares of Liquidia stock. The shares were sold at an average price of $37.43, for a total value of $768,550.19.

Liquidia Trading Up 4.0%

Liquidia stock traded up $1.41 during trading on Wednesday, hitting $36.61. The company’s stock had a trading volume of 1,015,932 shares, compared to its average volume of 1,932,669. The stock’s fifty day moving average is $37.81 and its 200 day moving average is $31.70. Liquidia Corporation has a 1-year low of $11.26 and a 1-year high of $46.67. The stock has a market capitalization of $3.23 billion, a price-to-earnings ratio of -44.11 and a beta of 0.52. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The firm had revenue of $92.02 million for the quarter, compared to analyst estimates of $87.49 million. The firm’s revenue was up 3072.4% on a year-over-year basis. As a group, equities research analysts predict that Liquidia Corporation will post -1.51 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on LQDA shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Thursday, January 22nd. Needham & Company LLC upped their price objective on Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. BTIG Research increased their target price on Liquidia from $49.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Finally, HC Wainwright boosted their price target on Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.44.

Institutional Investors Weigh In On Liquidia

Large investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP acquired a new position in shares of Liquidia during the 4th quarter valued at $3,148,000. Invesco Ltd. increased its holdings in Liquidia by 428.3% in the 4th quarter. Invesco Ltd. now owns 420,621 shares of the company’s stock valued at $14,507,000 after purchasing an additional 341,009 shares in the last quarter. XTX Topco Ltd purchased a new position in Liquidia in the fourth quarter valued at about $1,214,000. nVerses Capital LLC purchased a new position in Liquidia in the fourth quarter valued at about $335,000. Finally, Occudo Quantitative Strategies LP acquired a new position in Liquidia during the 4th quarter worth approximately $3,107,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).